Report cover image

Generics in Spain

Publisher MarketLine
Published Dec 18, 2025
Length 44 Pages
SKU # MTLN21020626

Description

Generics>in>Spain

Summary

>Generics>in>Spain>industry>profile>provides>top-line>qualitative>and>quantitative>summary>information>including:>market>size>(value>2019-24,>and>forecast>to>2029).>The>profile>also>contains>descriptions>of>the>leading>players>including>key>financial>metrics>and>analysis>of>competitive>pressures>within>the>market.

Key>Highlights
  • A>generic>drug>is>defined>as>a>copy>of>an>ethical>(prescription)>drug>formerly>protected>by>patents>that>have>now>expired.>Both>unbranded>generics>and>branded>generics>are>included>in>our>market>scope.>However,>off-patent>drugs>that>continue>to>be>offered>by>the>original>manufacturer>under>the>original>name,>and>which>form>part>of>the>'generic-eligible'>market,>are>not>included.>Market>value>is>evaluated>at>ex-factory>prices.>Market>volume>refers>to>the>proportion>of>the>total>ethical>pharmaceutical>market>in>a>country>or>region>that>is>made>up>of>generic>drugs.>Thus,>it>is>a>measure>of>the>market>share>held>by>generics,>rather>than>a>direct>measure>of>the>total>market>volume.>Regional>volumes>are>calculated>as>averages>of>countries>that>comprise>the>region>where>volume>data>exists.
  • The>Spanish>generics>market>recorded>revenues>of>$7.3>billion>in>2024,>representing>a>compound>annual>growth>rate>(CAGR)>of>3.7%>between>2019>and>2024.
  • Market>consumption>volume>increased>with>a>CAGR>of>1.0%>between>2019>and>2024,>reaching>a>total>of>47.5%>of>total>pharma>volume>in>2024.
  • In>2024,>the>revenue>of>the>Spanish>generics>market>experienced>an>annual>growth>of>4.8%.>The>market’s>growth>is>driven>by>the>rising>prevalence>of>chronic>diseases>such>as>diabetes,>hypertension,>and>cardiovascular>conditions,>increasing>the>demand>for>affordable,>long-term>medications.
Scope
  • Save>time>carrying>out>entry-level>research>by>identifying>the>size,>growth,>major>segments,>and>leading>players>in>the>generics>market>in>Spain
  • Use>the>Five>Forces>analysis>to>determine>the>competitive>intensity>and>therefore>attractiveness>of>the>generics>market>in>Spain
  • Leading>company>profiles>reveal>details>of>key>generics>market>players’>global>operations>and>financial>performance
  • Add>weight>to>presentations>and>pitches>by>understanding>the>future>growth>prospects>of>the>Spain>generics>market>with>five>year>forecasts
Reasons>to>Buy
  • What>was>the>size>of>the>Spain>generics>market>by>value>in>2024?
  • What>will>be>the>size>of>the>Spain>generics>market>in>2029?
  • What>factors>are>affecting>the>strength>of>competition>in>the>Spain>generics>market?
  • How>has>the>market>performed>over>the>last>five>years?
  • What>are>the>main>segments>that>make>up>Spain's>generics>market?

Table of Contents

44 Pages
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. What strategies do the leading players follow?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Ltd
8.2. Novartis AG
8.3. Viatris Inc
8.4. Esteve Pharmaceuticals SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Spain generics market value: $ million, 2019-24
Table 2: Spain generics market volume: % of total pharma volume, 2019-24
Table 3: Spain generics market geography segmentation: $ million, 2024
Table 4: Spain generics market value forecast: $ million, 2024-29
Table 5: Spain generics market volume forecast: % of total pharma volume, 2024-29
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Novartis AG: Key Facts
Table 10: Novartis AG: Annual Financial Ratios
Table 11: Novartis AG: Key Employees
Table 12: Viatris Inc: Key Facts
Table 13: Viatris Inc: Annual Financial Ratios
Table 14: Viatris Inc: Key Employees
Table 15: Esteve Pharmaceuticals SA: Key Facts
Table 16: Esteve Pharmaceuticals SA: Key Employees
Table 17: Spain Size of Population (Million), 2020-24
Table 18: Spain Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 19: Spain GDP (Current Prices, $ Billion), 2020-24
Table 20: Spain Inflation, 2020-24
Table 21: Spain Consumer Price Index (Absolute), 2020-24
Table 22: Spain Exchange Rate, 2019-24
List of Figures
Figure 1: Spain generics market value: $ million, 2019-24
Figure 2: Spain generics market volume: % of total pharma volume, 2019-24
Figure 3: Spain generics market geography segmentation: % share, by value, 2024
Figure 4: Spain generics market value forecast: $ million, 2024-29
Figure 5: Spain generics market volume forecast: % of total pharma volume, 2024-29
Figure 6: Forces driving competition in the generics market in Spain, 2024
Figure 7: Drivers of buyer power in the generics market in Spain, 2024
Figure 8: Drivers of supplier power in the generics market in Spain, 2024
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Spain, 2024
Figure 10: Factors influencing the threat of substitutes in the generics market in Spain, 2024
Figure 11: Drivers of degree of rivalry in the generics market in Spain, 2024

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us